Recent Updates
Recently added Catalysts
LXRX Positive Sentiment

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Lexicon Pharmaceuticals announced positive results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial. The analysis showed that sotagliflozin is effective across different baseline blood pressure levels in patients with recent worsening heart failure. These findings were presented at the ESC Congress 2026 and published in JACC: Heart Failure.

Market Sentiment Analysis

POSITIVE FACTORS

  • Demonstrated consistent results of sotagliflozin across varying blood pressure levels.
  • Findings presented at a major conference, enhancing visibility.
  • Published in a reputable journal, JACC: Heart Failure.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus

Full Press Release Details

Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure THE WOODLANDS, Texas, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial evaluating the efficacy

Frequently Asked Questions

What is the SOLOIST-WHF trial?

The SOLOIST-WHF trial is a Phase 3 study evaluating the efficacy of sotagliflozin in patients with worsening heart failure.

What were the key findings of the new analysis?

The analysis showed consistent efficacy of sotagliflozin across different baseline blood pressure levels.

Where were the findings presented?

The findings were presented at the ESC Congress 2026.

In which journal were the findings published?

The findings were published in JACC: Heart Failure.

ShareAdd on Google
Tags: LXRX Viatris Investor Conferences Healthcare Lexicon Pharmaceuticals sotagliflozin heart failure ESC Congress Phase 3
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$191M liquidity · $3M/mo burn
~61 mo
Minimal dilution risk
Lead asset
SotagliflozinPhase 3
Type 1 Diabetes Mellitus →

Catalyst track record

+111%
best trade around LXRX's most recent catalyst

Peak hindsight return over a 120-day window, across 13 tracked FDA/PDUFA catalysts for LXRX.

See every catalyst's timing & PoA →